Close Menu

NEW YORK – Transplant diagnostics company CareDx reported on Wednesday after the close of the market that its preliminary revenues for the first quarter of 2020 are expected to rise 47 percent year over year, despite a recent lag in testing service volumes due to the COVID-19 pandemic.

The company also withdrew its previously announced revenue guidance for full-year 2020 because of uncertainties surrounding the impact of COVID-19. Management will provide additional information during its Q1 earnings conference call.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.